NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic gastrointestinal conditions, particularly disorders of the gut-brain interaction in both children and adults. Its main product, IB-Stim, is a percutaneous electrical nerve field stimulation device cleared for patients aged eight and older dealing with functional abdominal pain tied to irritable bowel syndrome, functional dyspepsia, and related nausea. The company also offers RED, a diagnostic tool for assessing neuromuscular function and rectal hypersensitivity. Listed on the NYSE American under the symbol NRXS, it draws investor interest due to its position in an under-penetrated pediatric GI market and growing insurance coverage.
Over the last 30 days, NRXS declined approximately 46%, moving from a closing price near $7.92 down to roughly $4.27. This was a gradual erosion through November rather than one sharp drop, with several sessions showing higher volume as selling intensified. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking at the last quarter provides more context. Starting from around $6.27 three months earlier, the shares advanced through September and October, hitting an intraday high near $8.05 before reversing in November. That leaves the stock down about 32% over the full three-month stretch, with the earlier autumn gains fully erased after the third-quarter update.
The main trigger was the third-quarter 2026 earnings release. NeurAxis reported revenue of about $2.03 million, up 150% year over year, with gross margin around 86.6% and an average selling price near $1,045 per device. Yet the net loss more than tripled to roughly $6.55 million, largely from a sizable non-cash stock-compensation expense and higher spending on commercial and clinical efforts.
Investor focus stayed on the balance sheet and share count rather than the revenue line. Shares outstanding increased more than 40% year over year as equity was issued to support operations, which diluted per-share value even while revenue grew. With cash in the low single-digit millions and ongoing operating losses, attention turned to cash burn rates and whether growth could keep pace with dilution. The technical break below key moving averages added to the pressure.
The three-month picture shows a business with structural improvements running into financing questions. The January 1, 2026 launch of a permanent Category I CPT code for IB-Stim created a clearer reimbursement path, expanding payer coverage and supporting better pricing and volumes. This helped fuel revenue gains and lifted the stock through the fall. From what I see, the new code remains a meaningful longer-term positive.
Still, the funding approach stayed dilutive, and the earnings report highlighted the gap between revenue growth and bottom-line results. As the sales team expanded and clinical work advanced, expenses outpaced revenue on a GAAP basis. The quarter’s pullback reflects investors weighing how quickly reimbursement gains can deliver sustainable per-share value.
Several elements will influence the path ahead. Reimbursement progress stays central, including further adoption of the Category I CPT code, new payer decisions, and movement on the Veterans Administration channel. Management has also noted plans to start a large multi-center adult study for functional dyspepsia, which could expand the market over time.
Financially, attention will likely stay on cash use, share-count trends, and whether operating leverage improves as the commercial organization matures. Future quarterly reports and any capital raises will be important checkpoints. I’m watching this closely because these elements carry real risk alongside the growth outlook.
One resource I turn to when assessing names like this is Tickeron’s AI Trading Bots. These automated strategies draw from a broad set of models monitoring thousands of tickers and can highlight how different approaches are currently positioned, offering another layer of perspective alongside traditional research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
NRXS saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 68 similar instances where the indicator turned negative. In 64 of the 68 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 27 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NRXS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NRXS crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NRXS entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 123 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (3.596). P/E Ratio (-8.211) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology